The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.
Here we present nonconfidential company information about a subset of awardees ready to attract third-party collaborators and investors.
AfaSci, Inc., developing novel non-opioid analgesics for chronic pain.
AfaSci Executive Summary(pdf, 275 KB)
Aquilus Pharmaceuticals is a biotech company focused on the treatment and management of amyotrophic lateral sclerosis (ALS), neuropathic pain and other neurological disorders.
Aquilus Pharmaceuticals Executive Summary(pdf, 167 KB)
Aquilus Pharmaceuticals Summary Slide Deck(pdf, 857 KB)
AXONIS Therapeutics is advancing breakthrough drug discoveries to develop a pipeline of first-in-class neuron-reviving therapeutics for neurological disorders, to make a real difference for patients, their families, and the global healthcare system.
AXONIS Therapeutics Executive Summary(pdf, 198 KB)
Chemeleon has created a platform technology for an instrument-free, in vitro diagnostic assay that provides a rapid, visible, colorimetric readout in minutes for the detection of cerebrospinal fluid leaks at the point-of-care that will be extended to an array of other markets and analytes (ex., viruses, proteins, drugs, etc.)
Chemeleon Executive Summary(pdf, 250 KB)
Eysz Inc., is building a digital health platform for neurology - starting with Epilepsy - that will analyze eye-movement data to reliably quantitate seizures and neurocognitive symptoms to enable clinicians to deliver personalized medicine for their patients.
Eysz Executive Summary(pdf, 1092 KB)
Great Lakes NeuroTechnologies, the leader in remote monitoring of movement disorders, markets KinesiaU™, enabling doctors to provide personalized, efficient, accurate therapy titration with fewer office visits, saving time and money.
Great Lakes Neurotechnologies Executive Summary(pdf, 275 KB)
Neurexis Therapeutics, Neuroprotective Peptides for Cerebral Ischemia.
Neurexis Therapeutics Executive Summary(pdf, 1274 KB)
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS.
Pathmaker Neurosystems Executive Summary(pdf, 532 KB)
PolyCore Thereapeutics LLC is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders.
PolyCore Therapeutics Executive Summary(pdf, 1056 KB)
Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.
Rebion Executive Summary(pdf, 590 KB)
Rumi Scientific's platform makes it faster and more predictive to perform drug discovery in the CNS by identifying compounds which reverse the disease state at the cellular and tissue levels in large scale screenings, resulting in novel and better targets in the neurodegenerative and neurodevelopmental areas.
Rumi Scientific Executive Summary(pdf, 172 KB)
South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.
South Rampart Pharma Executive Summary(pdf, 521 KB)
Tellus Therapeutics is a neonatal care company whose mission is to develop safe and effective treatments for newborns in the neonatal intensive care unit (NICU).
Tellus Therapeutics Executive Summary(pdf, 269 KB)